
What is claimed is:

1. A compound of formula (II)



(II)

or a pharmaceutically acceptable salt thereof, wherein:

R is selected from C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, C_1-C_8 alkoxy, C_5-C_{10} aryl, -C(=O)R^7, -C(=S)R^7, -C(=NR^7)R^8, and -C(=NOR^7)R^8, wherein the alkyl, alkenyl, alkynyl, alkoxy and aryl are unsubstituted or substituted with one or more substituents;

R^1 is selected from -H, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, C_5-C_{10} aryl, C_5-C_{10} heterocycloalkyl, C_5-C_{10} heterocycloalkenyl, and C_5-C_{10} heteroaryl, wherein the alkyl, alkenyl, alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl and heteroaryl are unsubstituted or substituted with one or more substituents; and

R^2, R^7 and R^8 are independently selected from -H, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, C_5-C_{10} aryl, C_5-C_{10} heterocycloalkyl, C_5-C_{10} heterocycloalkenyl, and C_5-C_{10} heteroaryl, wherein the alkyl, alkenyl, alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl and heteroaryl are unsubstituted or substituted with one or more substituents.

2. The compound of claim 1, wherein R is C_1-C_8 alkyl, wherein the alkyl is unsubstituted or substituted with one or more substituents.

3. The compound of claim 1, wherein R is -C(=NOR^5)R^6; and R^5 and R^6 are independently C_1-C_8 alkyl.

4. The compound of claim 1, wherein R^1 is -H.

5. The compound of claim 3, wherein R^1 is C_1-C_8 alkyl, wherein the alkyl is unsubstituted or substituted with one or more substituents.

6. The compound of claim 1, wherein R^1 is C_1-C_4 alkyl.








7. The compound of claim 2, wherein R^1 is C_5-C_{10} aryl or C_5-C_{10} heteroaryl, wherein the aryl and heteroaryl are unsubstituted or substituted with one or more substituents.

8. The compound of claim 2, wherein R^1 is phenyl, wherein the phenyl is unsubstituted or substituted with halo.

9. The compound of claim 7, wherein R^2 is C_1-C_8 alkyl wherein the alkyl is unsubstituted or substituted with one or more substituents.

10. The compound of claim 8, wherein R^2 is C_1-C_4 alkyl.

11. The compound of claim 1, wherein the compound is selected from:


,

,

,

,

,

, and

.

12. A pharmaceutical composition comprising:
a compound of claim 1; and
a pharmaceutically acceptable excipient.

13. A method of modulating in vivo nitroxyl levels, comprising administering a compound of claim 1 to a subject in need thereof.

14. The compound of claim 2, wherein R is methyl.

15. The compound of claim 6, wherein R^1 is methyl.

16. The compound of claim 1, wherein R^2 is C_5-C_{10} aryl and wherein said aryl is unsubstituted or substituted with one or more substituents.

17. The compound of claim 16, wherein R^2 is phenyl and wherein said phenyl is unsubstituted or substituted with one or more substituents.

18. The compound of claim 16, wherein said aryl is substituted with one or more substituents selected from -F, -Cl, -Br, -I, -OH, $-NH_2$, -CN, $-NO_2$, -SH, =O, =S, =N-alkyl, alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, aryl, heteroaryl, heterocycloalkyl, heterocycloalkenyl, -C(=O)H, $-C(=O)NH_2$, -C(=O)OH, $-NH-C(=O)-NH_2$, $-NH-C(=S)-NH_2$, -S-CN, $-SO_2NH_2$, -COR', -C(O)OR', -C(O)NHR', -C(O)NR'R", -NHR', -NR'R", -SR', -SOR', $-SO_2R'$, and -OR', wherein R' and R" are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycloalkyl, and heterocycloalkenyl, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycloalkyl, and heterocycloalkenyl are unsubstituted.


19. The compound of claim 17, wherein said phenyl is substituted with one or more substituents selected from -F, -Cl, -Br, -I, -OH, $-NH_2$, -CN, $-NO_2$, -SH, =O, =S, =N-alkyl, alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, aryl, heteroaryl, heterocycloalkyl, heterocycloalkenyl, -C(=O)H, $-C(=O)NH_2$, -C(=O)OH, $-NH-C(=O)-NH_2$, $-NH-C(=S)-NH_2$, -S-CN, $-SO_2NH_2$, -COR', -C(O)OR', -C(O)NHR', -C(O)NR'R", -NHR', -NR'R", -SR', -SOR', $-SO_2R'$, and -OR', wherein R' and R" are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycloalkyl, and heterocycloalkenyl, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycloalkyl, and heterocycloalkenyl are unsubstituted.

20. The compound of claim 2, wherein R^1 is C_1-C_4 alkyl.

21. The compound of claim 20, wherein R and R^1 are each methyl.

What is claimed is:

1. A compound of formula (II)



(II)

or a pharmaceutically acceptable salt thereof, wherein:

R is selected from C_1-C_8 alkyl, and -C(=NOR^7)R^8;

R^1 is selected from -H, C_1-C_8 alkyl, and phenyl, wherein the phenyl is unsubstituted or substituted with one or more halo; and

R^2, R^7 and R^8 are independently selected from C_1-C_8 alkyl.

2. The compound of claim 1, wherein R is C_1-C_8 alkyl.

3. The compound of claim 1, wherein R is -C(=NOR^5)R^6; and R^5 and R^6 are independently C_1-C_4 alkyl.

4. The compound of claim 1, wherein R^1 is -H.








5. The compound of claim 3, wherein R^1 is C_1-C_8 alkyl.

6. The compound of claim 1, wherein R^1 is C_1-C_4 alkyl.

7. The compound of claim 2, wherein R^1 is phenyl, wherein the phenyl is unsubstituted or substituted with halo.

8. The compound of claim 7, wherein R^2 is C_1-C_4 alkyl.

9. The compound of claim 1, wherein the compound is selected from:


,

,

,

,

,

, and

.

10. A pharmaceutical composition comprising:

a compound of claim 1; and

a pharmaceutically acceptable excipient.

11. The compound of claim 2, wherein R is methyl.

12. The compound of claim 6, wherein R^1 is methyl.

13. The compound of claim 2, wherein R^1 is C_1-C_4 alkyl.

14. The compound of claim 13, wherein R and R^1 are each methyl.